Sharp Edge Labs: Discovering Drugs to Treat Genetic Disorders of Protein Trafficking.

Sharp Edge Labs
Sharp Edge LabsFriday, September 9th, 2016 at 4:30am
Here's a fun thing! Bill Newlin, our founding investor, and a champion of Sharp Edge Labs from the very beginning to today, did a radio interview on Pittsburgh Tech Council's TechVibe Radio where he discusses Sharp Edge, and another local tech company, LiquidX. Truly essential to have people like Bill in our community. You can listen here.

http://www.talkshoe.com/talkshoe/web/audioPop.jsp?episodeId=1108846&cmd=apop
2 1    View on Facebook
Sharp Edge Labs
Sharp Edge LabsTuesday, August 23rd, 2016 at 8:33am
A busy news-day for protein trafficking. This time, trafficking of lysosomes BETWEEN cells to deliver aggregated alpha-Synuclein in Parkinson's, enabling the spread by seeding cells with agregates from other cells. Wow.

https://www.sciencedaily.com/releases/2016/08/160822111818.htm
   View on Facebook
Sharp Edge Labs
Sharp Edge LabsTuesday, August 23rd, 2016 at 7:33am
Another twist in protein trafficking biology, illuminated by Stanford scientists.

http://www.scienceandtechnologyresearchnews.com/stanford-scientists-revise-decades-old-model-proteins-move-cells/
   View on Facebook
Sharp Edge Labs
Sharp Edge LabsTuesday, August 23rd, 2016 at 6:22am
Huge shout out to fellow Pittsburgh Life Science Company Thar Pharmaceuticals on filing their IPO to take their non-opioid pain medicine into Phase III Trials!
http://www.fiercebiotech.com/biotech/oral-pain-biotech-thar-pharmaceuticals-files-for-50m-public-offering
   View on Facebook
Sharp Edge Labs
Sharp Edge LabsFriday, March 25th, 2016 at 10:15am
Sharp Edge Labs announces a drug discovery alliance with stem cell pioneer ORIG3N to bring patients into the earliest stages of the drug discovery process (well, patients' stem cells that is).
http://finance.yahoo.com/news/orig3n-sharp-edge-labs-enter-213800553.html
5 1    View on Facebook
Off the Shelf
  • Monogenic Diseases
    Caused by a single gene alteration, monogenic diseases represent an area of high unmet need, but also of great therapeutic opportunity.
  • Trafficking Defects
    Many monogenic diseases result from a mutation that causes improper trafficking, the failure of the mutated protein to get to the right place inside the cell.
  • Patient-Driven Discovery
    Stem-Cell technology allows patients to participate in drug discovery programs at their earliest stages.
On the Bench
Sharp Edge Radar